de Bruijn H W, Suurmeijer A J, Sleijfer D T, Koops H S, Ockhuizen T, Willemse P H, Marrink J
Eur J Cancer Clin Oncol. 1982 Oct;18(10):911-6. doi: 10.1016/0277-5379(82)90236-x.
Serum SP-1 levels were measured serially in 94 patients with non-seminomatous germ cell tumors to evaluate its clinical significance as a tumor marker. In 12 out of 80 patients (15%) with active tumors serum SP-1 was found to be elevated, whereas serum HCG and AFP in the same sample were raised in 53 and 45% respectively. Elevation of serum SP-1 levels was always associated with raised HCG levels, and with AFP in 7 patients. During chemotherapy, serum SP-1 and HCG disappeared when a complete remission was obtained. In contrast to HCG, serum SP-1 failed to detect tumor progression in two patients. Serum HCG and AFP are superior as tumor markers to serum SP-1.
对94例非精原细胞瘤性生殖细胞肿瘤患者连续检测血清SP-1水平，以评估其作为肿瘤标志物的临床意义。在80例活动性肿瘤患者中，有12例（15%）血清SP-1升高，而同一样本中血清HCG和AFP升高的分别为53%和45%。血清SP-1水平升高总是与HCG水平升高相关，7例患者还与AFP升高相关。化疗期间，获得完全缓解时血清SP-1和HCG消失。与HCG不同，血清SP-1未能检测出2例患者的肿瘤进展。血清HCG和AFP作为肿瘤标志物优于血清SP-1。
